Compare CPB & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | ALGN |
|---|---|---|
| Founded | 1869 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.2B |
| IPO Year | N/A | N/A |
| Metric | CPB | ALGN |
|---|---|---|
| Price | $30.68 | $147.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $34.20 | ★ $190.50 |
| AVG Volume (30 Days) | ★ 5.5M | 1.5M |
| Earning Date | 12-09-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.10% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | 2.01 | ★ 5.16 |
| Revenue | ★ $10,253,000,000.00 | $3,982,622,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $1.15 | $3.44 |
| P/E Ratio | ★ $15.22 | $28.42 |
| Revenue Growth | ★ 6.40 | 0.56 |
| 52 Week Low | $29.39 | $122.00 |
| 52 Week High | $46.36 | $246.19 |
| Indicator | CPB | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 63.15 |
| Support Level | $30.00 | $132.64 |
| Resistance Level | $32.04 | $152.99 |
| Average True Range (ATR) | 0.71 | 4.83 |
| MACD | -0.02 | 1.06 |
| Stochastic Oscillator | 30.64 | 72.72 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.